GLRE screened as an ASYMMETRY candidate because the stock trades below stated book value while the balance sheet carries negligible financial debt, net cash, and ongoing repurchases. This is a selection criterion only: the due diligence values the company independently and concludes that the discount is attractive but depends on underwriting discipline and the Solasglas investment portfolio avoiding a drawdown.
Target P/B = peer median 0.96x +10% low-debt adjustment -5% investment-volatility adjustment = 1.01x. Cross-check using 8.5x normalized EPS of $2.60 gives $22.10, 9.8% below the $24.50 base FV. Sensitivity: +/-0.15x P/B moves FV by roughly +/-$3.30. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Book value anchor | Q1 2026 BVPS $22.00 x 1.01x target P/B | 22.20 |
| Net cash support | $67.37M net cash / 33.17M shares = $2.03/sh, included as floor quality | 0.80 |
| Buyback accretion | $5.0M Q1 repurchase plus discount-to-book accretion estimate | 0.60 |
| Q2 result risk reserve | Reserve for earnings-date volatility: 5% x $22.00 BVPS | -1.10 |
| Portfolio optionality | 25% probability x $8.00 Solasglas upside path over 12-18 months | 2.00 |
| FV base case | Explicit sum: 22.20 + 0.80 + 0.60 - 1.10 + 2.00 | 24.50 |
The asymmetry is driven by accounting-value support and capital allocation, not forced short covering. Insider ownership above 10% partially aligns incentives, but recent insider selling headlines require monitoring.
| Item | FY2023 | FY2024 | FY2025 | FY2026E | Guidance / note |
|---|---|---|---|---|---|
| Revenue / net premiums & investment income | ~$586M | ~$632M | ~$658M | $660-720M est. | Insurance revenue volatile by investment return |
| Net income | ~$87M | ~$71M | ~$81M TTM | $55-75M est. | Driven by underwriting plus Solasglas |
| Book value / sh. | ~$16.5 | ~$18.0 | ~$20.9 | $22.0-22.5 | Q1 2026 $22.00 |
| Debt / equity | <1% | <1% | ~0.7% | ~0.6% | Low financial leverage |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | N/D | 161.6 | N/D | 164.4 | 189.7 |
| Combined ratio % | N/D | 95.0% | N/D | N/D | N/D |
| EPS ($) | N/D | 0.01 | N/D | 1.44 | 1.05 |
| Book value / sh. | 18.87 | 18.97 | N/D | ~20.9 | 22.00 |
Business model - reinsurance plus investment portfolio
Reinsurance underwriting ~$650-720M FY26E revenue base profitable Specialty P&C reinsurance. Combined ratio below 100% is the key proof point for sustaining book value. Solasglas investment portfolio Book-value multiplier volatile Investment returns can add or subtract meaningfully from EPS and BVPS; this is the main non-underwriting risk. Capital return $5M Q1 buyback accretive Repurchases below book value increase BVPS, but the program is small relative to market cap.
Legal, regulatory and risk analysis
SWOT analysis
- +Book value per share of $22.00 versus sub-book market pricing.
- +Very low debt to equity.
- +Repurchases are accretive below book.
- +Q1 revenue exceeded consensus in screened data.
- −Small-cap liquidity and sparse consensus coverage.
- −Investment returns can dominate quarterly results.
- −No dividend support.
- −T-1 close was not fully cross-checkable.
- →Q2/2H earnings can close the discount to book.
- →More buybacks below book value.
- →P/B rerating if combined ratio stays below 100%.
- →Improved small-cap value sentiment.
- !Cat losses or adverse reserve development.
- !Solasglas drawdown reduces book value.
- !Earnings miss after the August catalyst.
- !Discount can persist without larger capital returns.
Summary by assessment area
- Book value and low leverage create an observable anchor.
- Net cash per share supports downside math.
- $24.50 base FV is +42.5% versus dated close.
- Bull case clears +60% only if book rerates.
- The floor is book value, subject to insurance and investment marks.
- Use fresh price before action.
Sources: price / market data: ChartExchange GLRE historical close 2026-07-27 $17.19; MarketBeat and Motley Fool quote pages for contemporaneous price-range sanity check. Official results / filings: Greenlight Re SEC Form 10-Q for Q1 2026 and SEC / company Q2 2025 release for historical combined-ratio context. Financial history: StockAnalysis GLRE statistics and financial pages, MarketBeat Q1 2026 earnings report. Market cap / shares / 52W: StockAnalysis statistics and MarketBeat stock profile. Short interest: N/D precise current figure during test; treated as low-to-moderate from market-data screens. Analyst target: N/D - no reliable dated consensus target found. Governance / insider / class action: MarketBeat July 2026 alert for insider-sales headline; no material class action, SEC investigation or short-seller report found in the test search. Peer comparables: UVE, HRTG, JRVR from public market-statistics pages and relative P/B/P/E screen estimates. Market data - last verified close 2026-07-27: GLRE $17.19, market cap approx. $540M, 52W range approx. $11.56-$19.39, shares outstanding approx. 33.17M. This document is for informational purposes only and does not constitute financial or investment advice.